Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme

1. A compound having formula (I)

or a pharmaceutically acceptable salt thereof, wherein

R 1 is hydrogen or alkyl;

R 2 is hydrogen;

R 3 is cycloalkyl, aryl, heteroaryl, heterocycle, —(CR a R b ) m —R 4 , —C(O)OR 5 , —C(R 5 )═N—O(R y ), —C(O)—R 5 , or —C(O)—N(R 5 )(R 6 );

m is 1, 2, 3 or 4;

R a , at each occurrence, is independently hydrogen, halogen, alkyl, alkenyl, haloalkyl, —OR 7a , —N(R 8 )(R 9 ), —C(O)OR 7b , —C(O)—R 7b , —C(O)—N(R 8 )(R 9 ), —(CR c R d ) p —OR 7a , —(CR c R d ) p —N(R 8 )(R 9 ), —(CR c R d ) p —C(O)OR 7b , —CR c R d ) p —C(O)—R 7b , —(CR c R d ) p —C(O)—N(R 8 )(R 9 ), aryl, heteroaryl, cycloalkyl, or heterocycle;

R b , at each occurrence, is independently hydrogen, halogen, alkyl, alkenyl, haloalkyl, —C(O)OR 7b , —C(O)—R 7b , —C(O)—N(R 8 )(R 9 ), —(CR c R d ) p —OR 7a , —(CR c R d ) p —N(R 8 )(R 9 ), —(CR c R d ) p —C(O)OR 7b , —(CR c R d ) p —C(O)—R 7b , —(CR c R d ) p —C(O)—N(R 8 )(R 9 ), aryl, heteroaryl, cycloalkyl, or heterocycle;

optionally, R a and R b together is ═CH 2 ;

R c and R d , at each occurrence, are each independently hydrogen, halogen, alkyl, or haloalkyl;

R y is hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkylalkyl, arylalkyl, heteroarylalkyl, or heterocyclealkyl;

R 4 is hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocycle, provided that when R 4 is hydrogen, alkyl or haloalkyl, then at least one R a is —OR 7a , —N(R 8 )(R 9 ), —C(O)OR 7b , —C(O)—R 7b , —C(O)—N(R 8 )(R 9 ), —(CR c R d ) p —OR 7a , —(CR c R d ) p —N(R 8 )(R 9 ), —(CR c R d ) p —C(O)OR 7b , —(CR c R d ) p —C(O)—R 7b , or —(CR c R d ) p —C(O)—N(R 8 )(R 9 ); or R a and R b together is ═CH 2 ;

R 5 , at each occurrence, is independently alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkylalkyl; arylalkyl, heteroarylalkyl, of heterocyclealkyl;

wherein each of the cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkyl moiety of the cycloalkylalkyl, aryl moiety of the arylalkyl, heteroaryl moiety of the heteroarylalkyl, and heterocycle moiety of the heterocyclealkyl, as represented by R 3 , R a , R b , R 4 , R 5 , and R y , is independently unsubstituted or further substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of alkyl, halogen, haloalkyl, oxo, —OR 10 , —S(R 14 ), —S(O) 2 R 15 , —S(O) 2 N(R 11 )(R 12 ), —N(R 11 )(R 12 ), —C(O)OR 10 , —C(O)O(trialkylsilylalkyl), —C(O)N(R 11 )(R 12 ), —(CR e R f ) q —OR 10 , —(CR e R f ) q —N(R 11 )(R 12 ), —(CR 11 R 12 )C(O)OR 10 , —(CR e R f ) q —C(O)N(R 11 )(R 12 ), G 1 , and ═N—O(R 10 ),

R 6 , R 9 and R 12 , at each occurrence, are each independently hydrogen, alkyl or haloalkyl;

R 7a , at each occurrence, is each independently hydrogen, alkyl, haloalkyl, —N═C(H)R 13a , —(CR g R h ) r —C(O)OR 13 , or G 1 ,

R 7b and R 10 , at each occurrence; are each independently hydrogen, alkyl haloalkyl, —(CR g R h ) r —C(O)OR 13 , or G 1 ,

R 8 and R 11 , at each occurrence, are each independently hydrogen, alkyl, haloalkyl, —S(O) 2 —R 13a , —S(O) 2 —N(R 13 )(R 14 ), —C(O)OR 13 , —C(O)N(R 13 )(R 14 ), or G 1 ;

p, q, and r, at each occurrence, are each independently 1, 2, 3, or 4;

R e , R f , R g , and R h , at each occurrence, are each independently hydrogen, halogen, alkyl, or haloalkyl;

R 14 , at each occurrence, is independently hydrogen, alkyl or haloalkyl;

R 15 , at each occurrence, is independently alkyl, haloalkyl, or G 1 ;

R 13 , at each occurrence, is independently hydrogen, alkyl, haloalkyl, or G 1 ;

R 13a , at each occurrence, is independently alkyl, haloalkyl, or G 1 ; and

G 1 , at each occurrence, is independently aryl, heteroaryl, cycloalkyl, heterocycle, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocyclealkyl, wherein the aryl, heteroaryl, cycloalkyl, heterocycle, aryl moiety of the arylalkyl, heteroaryl moiety of the heteroarylalkyl, cycloalkyl moiety of the cycloalkylalkyl, and heterocycle moiety of the heterocyclealkyl, are each independently unsubstituted or further substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, halogen, —CN, —NO 2 , —OH, —O(alkyl), —NH 2 , —N(H)(alkyl), —N(alkyl) 2 , —C(O)OH, —C(O)O(alkyl), —C(O)NH 2 , —C(O)N(alkyl), —C(O)N(alkyl) 2 , haloalkyl, and alkyl substituted with one substituent selected from the group consisting of —CN, —NO 2 , —OH, —O(alkyl), —NH 2 , —N(H)(alkyl), —N(alkyl) 2 , —C(O)OH, —C(O)O(alkyl), —C(O)NH 2 , —C(O)N(H)(alkyl), and —C(O)N(alkyl) 2 .

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is cycloalkyl or heterocycle.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is formula (a)

wherein

R 1k and R 2k together with the carbon atom to which they are attached form a cycloalkyl or a heterocycle ring, each of which is optionally further substituted with 1, 2, 3, 4 of 5 substituents selected from the group consisting of alkyl, halogen, haloalkyl, oxo, —OR 10 , —S(R 14 ), —S(O) 2 R 15 , —S(O) 2 N(R 11 )(R 12 ), —N(R 11 )(R 12 ), —C(O)OR 10 , —C(O)O (trialkylsilylalkyl), —C(O)N(R 11 )(R 12 ), —(CR e R f ) q —OR 10 , —(CR e R f ) q N(R 12 ), —(CR e R f ) q —C(O)OR 10 , —(CR e R f ) q —C(O)N(R 11 )(R 12 ), and ═N—O(R 10 ),

R 3k is —OR 10 , —N(R 11 )(R 12 ), —C(O)OR 10 , or —C(O)O(trialkylsilylalkyl), and

R e , R f , q, R 10 , R 11 , R 12 , R 14 , and R 15 are as defined in claim 1 .

4. The compound of claim 1 , of a pharmaceutically acceptable salt thereof, wherein R 3 is aryl, unsubstituted or substituted, with 1, 2, 3, 4 or 5 substituents selected from the group consisting of alkyl, haloalkyl, halogen, —OR 10 , —S(R 14 ), —S(O) 2 R 15 , —S(O) 2 N(R 11 )(R 12 ), —N(R 11 )(R 12 ), —C(O)OR 10 , —C(O)O(trialkylsilylalkyl), —C(O)N(R 11 )(R 12 ), —(CR e R f ) q —OR 10 , —(CR e R f ) q —N(R 11 )(R 12 ), —(CR e R f ) q —C(O)OR 10 , —(CR e R f ) q —C(O)N(R 11 )(R 12 ), and G 1 , and R e , R f , q, R 10 , R 11 , R 12 , R 14 , R 15 , and G 1 are as defined in claim 1 .

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is —(CR 8 R b ) m —R 4 , wherein

R a , at each occurrence, is independently hydrogen, halogen, alkyl, alkenyl, haloalkyl, —OR 7a , —N(R 8 )(R 9 ), —C(O)OR 7b , —C(O)—R 7b , —C(O)—N(R 8 )(R 9 ), —(CR c R d ) p —OR 7a , —(CR c R d ) p —N(R 8 )(R 9 ), —(CR c R d ) p —C(O)OR 7b , —(CR c R d ) p —C(O)—R 7b , —(CR c R d ) p —C(O)—N(R 8 )(R 9 ), aryl, heteroaryl, cycloalkyl, or heterocycle;

R b , at each occurrence, is independently hydrogen, halogen, alkyl, alkenyl, haloalkyl, —C(O)OR 7b , —C(O)—R 7b , —C(O)—N(R 8 )(R 9 ), —(CR c R d ) p —OR 7a , —(CR c R d ) p —N(R 8 )(R 9 ), —(CR c R d ) p —C(O)OR 7b , —(CR c R d ) p —C(O)—R 7b , —(CR c R d ) p —C(O)—N(R 8 )(R 9 ), aryl, heteroaryl, cycloalkyl, or heterocycle,

of R a and R b together is ═CH 2 ; and

m, p, R c , R d , R 4 , R 7a , R 7b , R 8 , and R 9 are as defined in claim 1 .

6. The compound of claim 5 or a pharmaceutically acceptable salt thereof, wherein R a and R b , at each occurrence, are each independently hydrogen, alkyl, alkenyl, halogen or haloalkyl, and R 4 is cycloalkyl, aryl, heteroaryl, or heterocycle.

7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 is formula (b)

wherein

R a and R b , at each occurrence, are each independently hydrogen, halogen, alkyl, alkenyl, or haloalkyl;

R 1k and R 2k together with the carbon atom to which they are attached form a cycloalkyl or heterocycle ring, wherein each of the ring is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, halogen, haloalkyl, oxo, —OR 10 , —S(R 14 ), —S(O) 2 R 15 , —S(O) 2 N(R 11 )(R 12 ), —N(R 11 )(R 12 ), —C(O)OR 10 , —C(O)O(trialkylsilylalkyl), —C(O)N(R 11 )(R 12 ), —(CR e R f ) q —OR 10 , —(CR e R f ) q —N(R 11 )(R 12 ), —(CR e R f ) q —C(O)OR 10 , —(CR e R f ) q —C(O)N(R 11 )(R 12 ), and ═N—O(R 10 ),

R 3k is —OR 10 , —N(R 11 )(R 12 ), or —C(O)OR 10 , and

R e , R f , q, R 10 , R 11 , R 12 , R 14 , and R 15 are as defined in claim 1 .

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is formula (c)

wherein

R b is hydrogen, halogen, alkyl, alkenyl, —C(O)OR 7b , haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocycle,

R a is OR 7a , N(R 8 )(R 9 ), or —C(O)OR 7b ,

or R 8 and R b together is ═CH 2 ;

R 4 is hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocycle, and

R 7a , R 7b , R 8 , and R 9 are as defined in claim 1 .

9. The compound of claim 8 or a pharmaceutically acceptable salt thereof, wherein

R 7a is hydrogen, C 1-6 alkyl, haloalkyl, —(CR g R h ) r —C(O)OR 13 , unsubstituted or substituted phenyl, and

R 13 , R g , R h , R 7b , and R 9 are each independently hydrogen, C 1-6 alkyl, or haloalkyl.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is formula (d)

wherein

R 1b is hydrogen, alkyl, alkenyl, halogen, —C(O)OR 7b , haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocycle, R 1a is OR 7a , N(R 8 )(R 9 ) or —C(O)OR 7b , and R 2a and R 2b , at each occurrence, are independently hydrogen, halogen, alkyl, alkenyl, or haloalkyl, or

R 2b is hydrogen, alkyl, alkenyl, halogen, —C(O)OR 7b , haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocycle, R 2a is OR 7a , N(R 8 )(R 9 ) or —C(O)OR 7b , and R 1a and R 1b , at each occurrence, are independently hydrogen, halogen, alkyl, alkenyl, or haloalkyl;

each of the aryl, heteroaryl, cycloalkyl, or heterocycle as represented by R 1b and R 2b is independently unsubstituted or further substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of 1, 2, 3, 4 or 5 substituents selected from the group consisting of alkyl, halogen, haloalkyl, oxo, —OR 10 , —S(R 14 ), —S(O) 2 R 15 , —S(O) 2 N(R 11 )(R 12 ), —N(R 11 )(R 12 ), —C(O)OR 10 , —C(O)O(trialkylsilylalkyl), —C(O)N(R 11 )(R 12 ), —(CR e R f ) q —OR 10 , —(CR e R f ) q —N(R 11 )(R 12 ), —(CR e R f ) q —C(O)OR 10 , —(CR e R f ) q —C(O)N(R 11 )(R 12 ), G 1 , and ═N—O(R 10 ),

R 4 is hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocycle, and

R 7a , R 7b , R 8 , R e , R f , R 9 , R 10 , R 11 , R 12 , R 14 , R 15 , and q, are as defined in claim 1 .

11. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 is —C(O)—R 5 .

12. The compound of claim 1 selected from the group consisting of

6-[(4-aminophenyl)ethynyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

6-(cyclohexylethynyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-methyl-6-(4-phenylbut-1-ynyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

1-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]cyclopentanol;

1-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]cyclopentanol;

4-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]tetrahydro-2H-pyran-4-ol;

4-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-2-cyclopentylbut-3-yn-2-ol;

4-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-2-phenylbut-3-yn-2-ol;

4-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1,1,1-trifluoro-2-phenylbut-3-yn-2-ol;

3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1,1-diphenylprop-2-yn-1-ol;

3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-phenylprop-2-yn-1-ol;

6-[4-methoxyphenyl)ethynyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-cyclopropyl-1-phenylprop-2-yn-1-ol;

6-[(4-methoxyphenyl)ethynyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1,1-bis(4-chlorophenyl)prop-2-yn-1-ol;

5-methyl-6-(3-morpholin-4-yl-3-phenylprop-1-ynyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-(1-methylcyclohexyl)-1-phenylprop-2-yn-1-ol;

3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-(3,4′-dichloro-1,1′-biphenyl-4-yl)prop-2-yn-1-ol;

1-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-3-(1,1′-biphenyl-4-yl)-4,4-dimethylpent-1-yn-3-ol;

methyl 4-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-2-hydroxy-2-phenylbut-3-ynoate;

N-{-1-[7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]cyclohexyl}-3-chlorobenzenesulfonamide;

N-{4-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]phenyl}-N′-(3-chlorophenyl)urea;

(1R,4R)-2-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol;

(1Z)-2-[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)prop-2-ynyl]-4-tert butylcyclohexanone oxime;

4-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-2-(4-isopropyl-2-methylcyclopentyl)but-3-yn-2-ol;

methyl {[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-phenylprop-2-ynyl]oxy}acetate;

{[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-phenylprop-2-ynyl]oxy}acetic acid;

{2-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]phenyl}methanol;

{3-[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-hydroxy-1-methylprop-2-ynyl]-2,2-dimethylcyclobutyl}acetic acid;

4-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-2-cyclobutylbut-3-yn-2-ol;

4-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-2-(3-methylcyclobutyl)but-3-yn-2-ol;

5-methyl-6-(3-phenylprop-1-ynyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

6-(3-cyclopentylprop-1-ynyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

6-[(1-aminocyclohexyl)ethynyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-cyclopentylprop-2-yn-1-ol;

3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-(2,4-dichlorophenyl)prop-2-yn-1-ol;

4-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-cyclopentyl-2-methylbut-3-yn-2-ol;

{4-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]-4-hydroxycyclohexyl}acetic acid;

methyl {4-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]-4-hydroxycyclohexyl}acetate;

(1R,4S)-2-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]bicyclo[2.2.1]heptan-2-ol;

(1R,2S,4R)-2-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol;

(1R,2R,4S)-2-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-ol;

tert-butyl {4-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]-4-hydroxycyclohexyl}acetate;

(1S,2S,4R)-2-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-ol;

(1S,2R,4S)-2-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol;

1-[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)prop-2-ynyl]cyclopentanol;

1-[(7-amino-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]cyclopentanol;

1-[3-(7-amino[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)prop-2-ynyl]cyclopentanol;

(1R,2S,4R)-2-[3-(7-amino-5-methyl[1,2,4]triazo[1,5-a]pyrimidin-6-yl)prop-2-ynyl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol;

methyl 1-[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)prop-2-ynyl]cyclohexanecarboxylate;

6-[3-(4-methoxyphenoxy)but-1-ynyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

(1R)-3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-phenylprop-2-yn-1-ol;

(1S)-3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-phenylprop-2-yn-1-ol;

4-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-phenylbut-3-yn-1-ol;

(trans)-ethyl 2-[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-hydroxyprop-2-ynyl]cyclopropanecarboxylate;

1-[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)prop-2-ynyl]cyclohexanecarboxylic acid;

1-[(7-amino-5-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]cyclopentanol;

3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-phenylprop-2-yn-1-one;

2-{3-[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-hydroxy-1-methylprop-2-ynyl]-2,2-dimethylcyclobutyl}acetamide;

(1R,2S,4R)-2-[(7-amino-5-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol;

1-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]cycloheptanol;

{[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-cyclopentylprop-2-ynyl]oxy}acetic acid;

({1-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]cyclopentyl}oxy)acetic acid;

3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-cyclohexylprop-2-yn-1-ol;

methyl 4-[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-hydroxyprop-2-ynyl]cyclohexanecarboxylate;

4-[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-hydroxyprop-2-ynyl]cyclohexanecarboxylic acid;

{3-[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-1-methyleneprop-2-ynyl]-2,2-dimethylcyclobutyl}acetic acid;

methyl 1-[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-o]pyrimidin-6-yl)prop-2-ynyl]cyclopentanecarboxylate;

2-(trimethylsilyl)ethyl 1-[3-(7-amino-5-methyl[1,2,4]triazolo[1,5-o]pyrimidin-6-yl)prop-2-ynyl]cyclohexanecarboxylate;

6-[(4-chlorophenyl)ethynyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

6-[(4-chlorophenyl)ethynyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

methyl 2-{4-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]phenyl}-2-methylpropanoate; and

ethyl 1-[4-(7-amino-5-methyl[1,2,4]triazolo[1,5-o]pyrimidin-6-yl)but-3-ynyl]-2-oxocyclopentanecarboxylate;

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.